Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Production of 177Lu at the new research reactor FRM-II: Irradiation yield of 176Lu(n,gamma)177Lu.

Literature DB >> 17900914

Production of 177Lu at the new research reactor FRM-II: Irradiation yield of 176Lu(n,gamma)177Lu.

Z Dvorakova¹, R Henkelmann, X Lin, A Türler, H Gerstenberg.

Abstract

Due to its physical and chemical characteristics, 177Lu is a very attractive radionuclide for use in nuclear medicine. This paper introduces a method for a precise calculation of the irradiation yield of 177Lu produced by neutron activation of 176Lu in a nuclear reactor. The calculation is based on the Westcott convention which requires the knowledge of the neutron flux parameters. In this work, the neutron flux parameters of the new research reactor FRM-II (Garching, Germany) were determined and the stability of thermal neutron flux and thermal neutron flux temperature was monitored. The comparison of theoretically calculated and experimentally determined yield for Lu176(n,gamma)Lu177 reaction is presented.

Mesh：

Substances：

Year: 2007 PMID： 17900914 DOI： 10.1016/j.apradiso.2007.08.013

Source DB: PubMed Journal: Appl Radiat Isot ISSN： 0969-8043 Impact factor: 1.513

Keyword Cloud
Cited

10 in total

Review 1. Production of (177)Lu for Targeted Radionuclide Therapy: Available Options.

Authors: Ashutosh Dash; Maroor Raghavan Ambikalmajan Pillai; Furn F Knapp
Journal: Nucl Med Mol Imaging Date: 2015-02-17

Review 2. Chemical aspects of metal ion chelation in the synthesis and application antibody-based radiotracers.

Authors: Eszter Boros; Jason P Holland
Journal: J Labelled Comp Radiopharm Date: 2018-03-12 Impact factor: 1.921

Review 3. A review of advances in the last decade on targeted cancer therapy using ¹⁷⁷Lu: focusing on ¹⁷⁷Lu produced by the direct neutron activation route.

Authors: Rubel Chakravarty; Sudipta Chakraborty
Journal: Am J Nucl Med Mol Imaging Date: 2021-12-15

Review 4. One decade of 'Bench-to-Bedside' peptide receptor radionuclide therapy with indigenous [¹⁷⁷Lu]Lu-DOTATATE obtained through 'Direct' neutron activation route: lessons learnt including practice evolution in an Indian setting.

Authors: Sandip Basu; Sudipta Chakraborty; Rahul V Parghane; Rohit Ranade; Pradeep Thapa; Ramesh V Asopa; Geeta Sonawane; Swapna Nabar; Hemant Shimpi; Ashok Chandak; K V Vimalnath; Vikas Ostwal; Anant Ramaswamy; Manish Bhandare; Vikram Chaudhari; Shailesh V Shrikhande; Bhawna Sirohi; Ashutosh Dash; Sharmila Banerjee
Journal: Am J Nucl Med Mol Imaging Date: 2020-08-25

5. [Lu]-DOTA-Tyr-octreotate: A Potential Targeted Radiotherapeutic for the Treatment of Medulloblastoma.

Authors: Ganesan Vaidyanathan; Donna J Affleck; Xiao-Guang Zhao; Stephen T Keir; Michael R Zalutsky
Journal: Curr Radiopharm Date: 2010

6. 177Lu-DOTA-HH1, a novel anti-CD37 radio-immunoconjugate: a study of toxicity in nude mice.

Authors: Ada H V Repetto-Llamazares; Roy H Larsen; Anna Maria Giusti; Elena Riccardi; Øyvind S Bruland; Pål Kristian Selbo; Jostein Dahle
Journal: PLoS One Date: 2014-07-28 Impact factor: 3.240

7. Specific radioactivity of neutron induced radioisotopes: assessment methods and application for medically useful 177Lu production as a case.

Authors: Van So Le
Journal: Molecules Date: 2011-01-19 Impact factor: 4.411

Production of 177Lu at the new research reactor FRM-II: Irradiation yield of 176Lu(n,gamma)177Lu.

Review 1. Production of (177)Lu for Targeted Radionuclide Therapy: Available Options.

Review 2. Chemical aspects of metal ion chelation in the synthesis and application antibody-based radiotracers.

Review 3. A review of advances in the last decade on targeted cancer therapy using ¹⁷⁷Lu: focusing on ¹⁷⁷Lu produced by the direct neutron activation route.

Review 4. One decade of 'Bench-to-Bedside' peptide receptor radionuclide therapy with indigenous [¹⁷⁷Lu]Lu-DOTATATE obtained through 'Direct' neutron activation route: lessons learnt including practice evolution in an Indian setting.

5. [Lu]-DOTA-Tyr-octreotate: A Potential Targeted Radiotherapeutic for the Treatment of Medulloblastoma.

6. 177Lu-DOTA-HH1, a novel anti-CD37 radio-immunoconjugate: a study of toxicity in nude mice.

7. Specific radioactivity of neutron induced radioisotopes: assessment methods and application for medically useful 177Lu production as a case.

8. Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma.

9. Separation of nuclear isomers for cancer therapeutic radionuclides based on nuclear decay after-effects.

10. Radionuclide generator-based production of therapeutic ¹⁷⁷Lu from its long-lived isomer ^177mLu.

Production of 177Lu at the new research reactor FRM-II: Irradiation yield of 176Lu(n,gamma)177Lu.

Review 1. Production of (177)Lu for Targeted Radionuclide Therapy: Available Options.

Review 2. Chemical aspects of metal ion chelation in the synthesis and application antibody-based radiotracers.

Review 3. A review of advances in the last decade on targeted cancer therapy using 177Lu: focusing on 177Lu produced by the direct neutron activation route.

Review 4. One decade of 'Bench-to-Bedside' peptide receptor radionuclide therapy with indigenous [177Lu]Lu-DOTATATE obtained through 'Direct' neutron activation route: lessons learnt including practice evolution in an Indian setting.

5. [Lu]-DOTA-Tyr-octreotate: A Potential Targeted Radiotherapeutic for the Treatment of Medulloblastoma.

6. 177Lu-DOTA-HH1, a novel anti-CD37 radio-immunoconjugate: a study of toxicity in nude mice.

7. Specific radioactivity of neutron induced radioisotopes: assessment methods and application for medically useful 177Lu production as a case.

8. Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma.

9. Separation of nuclear isomers for cancer therapeutic radionuclides based on nuclear decay after-effects.

10. Radionuclide generator-based production of therapeutic 177Lu from its long-lived isomer 177mLu.

Review 3. A review of advances in the last decade on targeted cancer therapy using ¹⁷⁷Lu: focusing on ¹⁷⁷Lu produced by the direct neutron activation route.

Review 4. One decade of 'Bench-to-Bedside' peptide receptor radionuclide therapy with indigenous [¹⁷⁷Lu]Lu-DOTATATE obtained through 'Direct' neutron activation route: lessons learnt including practice evolution in an Indian setting.

10. Radionuclide generator-based production of therapeutic ¹⁷⁷Lu from its long-lived isomer ^177mLu.